Baxter Raises Financial Outlook - Quick Facts

(RTTNews) - Baxter International Inc. (BAX) announced, for full-year 2017, based on the strong first quarter, the company now expects sales growth of approximately 1 to 2 percent on a reported basis or 2 to 3 percent on a constant currency basis, and earnings from continuing operations, before special items, of $2.20 to $2.28 per share for the full year. Adjusting for the impact of generic cyclophosphamide competition and selected strategic product exits, Baxter expects underlying constant currency sales growth of approximately 4 to 5 percent.

For the second quarter, the company expects flat sales growth on a reported basis, or approximately 2 percent on a constant currency basis. Adjusting for the impact of generic cyclophosphamide competition and selected strategic product exits, Baxter expects underlying constant currency sales growth of approximately 3 percent. The company expects earnings from continuing operations, before special items, of $0.55 to $0.57 per share.